RxDoctor Payments Data

Laveena Singla

Neurology · Flowood, MSNPI 1457702615

Payments from drug & device makers

What this record shows

15 manufacturers reported payments, led by Neuropace, Inc. at 59.1% of the total. Reporting peaked in 2024 at $2,203 and has fallen 83.7% since, to $360 in 2025.

$3,316in general payments, 2019–2025

Across 51 payments — averaging $65.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuropace, Inc.$2K
  • UCB, Inc.$303
  • SK Life Science, Inc.$227
  • AstraZeneca$188
  • Jazz Pharmaceuticals Inc.$172
  • Sunovion Pharmaceuticals Inc.$153
  • plus $313 from 9 others

What the payments were for

  • Travel & lodging$1,39242%
  • Food & beverage$1,92458%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,316 in reported general payments places this provider in the 55th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$60,298
Medicare patients
302
Services billed
651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate35$75,170
XcopriCenobamate52$68,364
FycompaPerampanel40$49,563
BriviactBrivaracetam23$34,405
NayzilamMidazolam25$17,051
Lacosamide67$4,696
Levetiracetam103$4,233
Rufinamide11$2,831
Divalproex Sodium ErDivalproex Sodium34$2,067
Divalproex Sodium28$1,259
Zonisamide29$775
Lamotrigine43$621
Topiramate29$569
Phenytoin Sodium Extended15$467
Clonazepam19$373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$153$75,17035 claims
SK Life Science, Inc.Xcopri$227$68,36452 claims
UCB, Inc.Briviact, Nayzilam$303$51,45748 claims
Eisai Inc.Fycompa$50$49,56340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 111 neurology providers in Mississippi.

Other neurology in Flowood

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →